[Use of soluble ozone in combined treatment of pulmonary tuberculosis: lipid peroxidation and blood antioxidative defense systems].
Changes in lipid peroxidation and blood antioxidative defense systems and red blood cell function were studied in 16 patients with prolonged progressive pulmonary tuberculosis in response to intravenous soluble ozone (SO) administration. There was a drastic rise in the activity of intraerythrocytic superoxide dismutase (SOD) and a reduction in intracellular malonic dialdehyde (MDA) levels. In the remaining patients, there was a decrease in the activity of SOD and an increase in intraerythrocytic MDA concentrations. Plasma catalase activity increased in all patients and MDA levels lowered. It is proposed that initial SO doses for patients with chronic pulmonary tuberculosis should be chosen on an individual basis by taking into account intraerythrocytic SOD-MDA changes due to SO initiation.
Belianin
I I
II
Abdullaev
R Iu
RIu
D000293:Adolescent; D000328:Adult; D000975:Antioxidants / Q000378:metabolism*; D015415:Biomarkers / Q000097:blood; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007424:Intracellular Fluid / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D010083:Oxidants, Photochemical / Q000008:administration & dosage*; D010126:Ozone / Q000008:administration & dosage*; D012720:Severity of Illness Index; D012995:Solubility; D013482:Superoxide Dismutase / Q000097:blood; D014397:Tuberculosis, Pulmonary / Q000097:blood* / Q000188:drug therapy
D000975:Antioxidants; D015415:Biomarkers; D010083:Oxidants, Photochemical; D008315:Malondialdehyde; D010126:Ozone; D013482:Superoxide Dismutase